Testicular steroid sulfatase overexpression is associated with Leydig cell dysfunction in primary spermatogenic failure

Andrology ◽  
2020 ◽  
Author(s):  
Maria C. Lardone ◽  
Ian N. Reyes ◽  
Eliana Ortiz ◽  
Antonio Piottante ◽  
Cristián Palma ◽  
...  
Keyword(s):  
Leydig Cell ◽  
Steroid Sulfatase ◽  
Cell Dysfunction ◽  
Spermatogenic Failure

scholarly journals Phthalate-Induced Fetal Leydig Cell Dysfunction Mediates Male Reproductive Tract Anomalies

2019 ◽  
Vol 10 ◽  
Author(s):  
Yiyan Wang ◽  
Chaobo Ni ◽  
Xiaoheng Li ◽  
Zhenkun Lin ◽  
Qiqi Zhu ◽  
...  
Keyword(s):  
Leydig Cell ◽  
Reproductive Tract ◽  
Male Reproductive Tract ◽  
Cell Dysfunction

scholarly journals CXCR4‐SF1 bifunctional adipose‐derived stem cells benefit for the treatment of Leydig cell dysfunction‐related diseases

2020 ◽  
Vol 24 (8) ◽  
pp. 4633-4645 ◽  
Author(s):  
Xue Li ◽  
Ao Xu ◽  
Kai Li ◽  
Jie Zhang ◽  
Qin Li ◽  
...  
Keyword(s):  
Stem Cells ◽  
Leydig Cell ◽  
Adipose Derived Stem Cells ◽  
Cell Dysfunction

Testicular Function After Cytotoxic Chemotherapy: Evidence of Leydig Cell Insufficiency

1999 ◽  
Vol 17 (5) ◽  
pp. 1493-1493 ◽  
Author(s):  
S. J. Howell ◽  
J. A. Radford ◽  
W.D.J. Ryder ◽  
S. M. Shalet
Keyword(s):  
Leydig Cell ◽  
Significant Proportion ◽  
Cytotoxic Chemotherapy ◽  
Good Evidence ◽  
Sex Hormone Binding Globulin ◽  
Total Testosterone ◽  
High Dose ◽  
Testicular Function ◽  
Cell Dysfunction ◽  
Significant Difference

PURPOSE: To evaluate testicular function in men after treatment with cytotoxic chemotherapy. PATIENTS AND METHODS: We measured testosterone, sex hormone–binding globulin (SHBG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) levels in 209 men after treatment with mechlorethamine, vinblastine, procarbazine, and prednisone, hybrid chemotherapy, or high-dose chemotherapy and in 54 healthy age-matched controls. RESULTS: The mean age of the patients was 38 years (range, 19 to 68 years), and all patients had received chemotherapy between 1 and 22 years previously. Patients had significantly higher mean LH (7.9 v 4.1 IU/L; P < .0001) and FSH levels (18.8 v 3.1 IU/L; P < .0001) than controls. There was no significant difference in mean total testosterone level between the patients and controls, but there was a trend toward a lower mean testosterone/SHBG ratio in the patients (0.63 v 0.7; P = .08). Analysis of the hormonal parameters using a model that allowed for the effects of increasing age on testicular function showed evidence of significant recovery of gonadal function in the first 10 years after treatment. Fifty-two percent of patients had LH levels at or above the upper limit of normal, and 32% of patients had increased LH with testosterone levels in the lower half of the normal range, suggesting a degree of Leydig cell impairment. CONCLUSION: In a significant proportion of men, there is good evidence of Leydig cell dysfunction after cytotoxic chemotherapy. The clinical significance of this Leydig cell dysfunction is not clear, but some of these men may benefit from testosterone replacement. Further studies are warranted.

LEYDIG CELL DYSFUNCTION AND GYNAECOMASTIA IN ADULT MALES TREATED WITH ALKYLATING AGENTS

1980 ◽  
Vol 12 (6) ◽  
pp. 553-556 ◽  
Author(s):  
N. M. FRIEDMAN ◽  
S. R. PLYMATE
Keyword(s):  
Leydig Cell ◽  
Alkylating Agents ◽  
Adult Males ◽  
Cell Dysfunction

scholarly journals Stem cell therapy for the treatment of Leydig cell dysfunction in primary hypogonadism

2016 ◽  
Vol 8 (10) ◽  
pp. 306 ◽  
Author(s):  
Taylor C Peak ◽  
Nora M Haney ◽  
William Wang ◽  
Kenneth J DeLay ◽  
Wayne J Hellstrom
Keyword(s):  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Leydig Cell ◽  
Cell Dysfunction

Evidence for Leydig Cell Dysfunction in Infertile Men with a Selective Increase in Plasma Follicle-Stimulating Hormone*

1987 ◽  
Vol 64 (6) ◽  
pp. 1194-1198 ◽  
Author(s):  
JOHN D. BOOTH ◽  
GEORGE R. MERRIAM ◽  
RICHARD V. CLARK ◽  
D. LYNN LORIAUX ◽  
RICHARD J. SHERINS
Keyword(s):  
Leydig Cell ◽  
Follicle Stimulating Hormone ◽  
Cell Dysfunction ◽  
Infertile Men ◽  
Selective Increase ◽  
Stimulating Hormone

LEYDIG CELL DYSFUNCTION AFTER COMBINATION CHEMOTHERAPY

The Lancet ◽  
1981 ◽  
Vol 318 (8245) ◽  
pp. 529
Author(s):  
Christina Wang ◽  
RonaldP. Ng ◽  
T.K. Chan ◽  
David Todd
Keyword(s):  
Combination Chemotherapy ◽  
Leydig Cell ◽  
Cell Dysfunction

scholarly journals A Possible Relation between Elevated FSH Levels and Leydig Cell Dysfunction in Azoospermic and Oligospermic Men

1980 ◽  
Vol 1 (3) ◽  
pp. 127-132 ◽  
Author(s):  
LUIS J. RODRIGUEZ-RIGAU ◽  
KEITH D. SMITH ◽  
EMIL STEINBERGER
Keyword(s):  
Leydig Cell ◽  
Cell Dysfunction

scholarly journals Serum Insulin-Like Factor 3 Levels during Puberty in Healthy Boys and Boys with Klinefelter Syndrome

2006 ◽  
Vol 91 (11) ◽  
pp. 4705-4708 ◽  
Author(s):  
Anne M. Wikström ◽  
Katrine Bay ◽  
Matti Hero ◽  
Anna-Maria Andersson ◽  
Leo Dunkel
Keyword(s):  
Aromatase Inhibitor ◽  
Leydig Cell ◽  
Klinefelter Syndrome ◽  
Pubertal Development ◽  
Bone Age ◽  
University Hospital ◽  
Initial Increase ◽  
Prospective Clinical Study ◽  
Testosterone Levels ◽  
Cell Dysfunction

Abstract Context: Levels of the Leydig cell-specific hormone insulin-like factor 3 (INSL3) are incompletely characterized in boys during pubertal development. Objective: The objective of the study was to characterize changes in INSL3 levels during spontaneous puberty in healthy boys, boys with aromatase inhibitor-induced hypergonadotropic hyperandrogenism, and boys with Leydig cell dysfunction. Design: This was a prospective clinical study. Setting: The study was conducted at a university hospital pediatric endocrinology outpatient clinic. Patients: Patients included 30 healthy boys with idiopathic short stature (ISS) aged 9.0–14.5 yr and 14 boys with Klinefelter syndrome (KS) aged 10–13.9 yr. Intervention: In ISS boys, intervention included aromatase inhibitor letrozole or placebo for 24 months. Main Outcome Measures: Serum INSL3 levels in relation to bone age, Tanner pubertal stages, and LH and testosterone levels were measured. Results: Onset of puberty was associated with a significant increase in INSL3 levels from 0.06 ± 0.01 ng/ml at Tanner G1 to 0.32 ± 0.16 ng/ml at G2 (P &lt; 0.0001). Adult INSL3 levels (≥0.55 ng/ml) were attained at bone age 13–14 yr. ISS boys with letrozole-induced hypergonadotropic hyperandrogenism had, after 12 months of therapy, higher INSL3 levels than did placebo treated (0.85 ± 0.54 vs. 0.26 ± 0.17 ng/ml, P &lt; 0.01). In KS boys during spontaneous puberty, after an initial increase similar to that in healthy boys, INSL3 concentrations leveled off despite hyperstimulation by LH. Positive correlations occurred between serum INSL3 and LH and between INSL3 and testosterone levels in all three groups (P &lt; 0.0001). Conclusions: In boys, the Leydig cell-specific hormone INSL3 may serve as a new marker for onset and progression of puberty. Pubertal increase in INSL3 levels seems to depend on LH. In KS subjects, INSL3 concentrations indicate Leydig cell dysfunction from midpuberty onward.

Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors

2017 ◽  
Vol 84 ◽  
pp. 9-17 ◽  
Author(s):  
M. Bandak ◽  
N. Jørgensen ◽  
A. Juul ◽  
J. Lauritsen ◽  
P.S. Oturai ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Testicular Cancer ◽  
Cancer Survivors ◽  
Systemic Inflammation ◽  
Leydig Cell ◽  
Cell Dysfunction ◽  
Testicular Cancer Survivors
Sign in / Sign up

Export Citation Format

Share Document